Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711341 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1POLBKDM4EHTT | |
| SCHEMBL6717840 | 0.84 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KDM4EHTTTERT | |
| SCHEMBL6338203 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1POLBTERTKMT2A | |
| SCHEMBL1295 | 0.78 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1POLBKDM4EHTT | |
| SCHEMBL3583425 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1POLBKDM4ETERT | |
| SCHEMBL1452 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1TERTKMT2ALMNA | |
| SCHEMBL28038421 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1POLBKDM4EHTT | |
| SCHEMBL6443705 | 0.72 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HTTPDE5ATERT | |
| SCHEMBL28038719 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTKMT2AMAPT | |
| SCHEMBL7847021 | 0.70 | SMN1; SMN2 (0.90) | SMN1; SMN2TERTKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | SMN1; SMN2 4046/4885ALDH1A1 1021/4885POLB 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.